Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads
Open accessThe DOI matches its Crossref record; 70 of the 71 references it cites were found in a registry or an index.
Abstract
Several promising plasma biomarkers for Alzheimer's disease have been recently developed, but their neuropathological correlates have not yet been fully determined. To investigate and compare independent associations between multiple plasma biomarkers (p‐tau181, p‐tau217, p‐tau231, Aβ42/40, GFAP, and NfL) and neuropathologic measures of amyloid and tau, we included 105 participants from the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND) with antemortem plasma samples and a postmortem neuropathological exam, 48 of whom had longitudinal p‐tau217 and p‐tau181. When simultaneously including plaque and tangle loads, the Aβ42/40 ratio and p‐tau231 were only associated with plaques (ρ Aβ42/40 [95%CI] = −0.53[−0.65, −0.35], ρ p‐tau231 [95%CI] = 0.28[0.10, 0.43]), GFAP was only associated with tangles (ρ GFAP [95%CI] = 0.39[0.17, 0.57]), and p‐tau217 and p‐tau181 were associated with both plaques (ρ p‐tau217 [95%CI] = 0.40[0.21, 0.56], ρ p‐tau181 [95%CI] = 0.36[0.15, 0.50]) and tangles (ρ p‐tau217 [95%CI] = 0.52[0.34, 0.66]; ρ p‐tau181 [95%CI] = 0.36[0.17, 0.52]). A model combining p‐tau217 and the Aβ42/40 ratio showed the highest accuracy for predicting the presence of Alzheimer's disease neuropathological change (ADNC, AUC[95%CI] = 0.89[0.82, 0.96]) and plaque load ( R 2 = 0.55), while p‐tau217 alone was optimal for predicting tangle load ( R 2 = 0.45). Our results suggest that high‐performing assays of plasma p‐tau217 and Aβ42/40 might be an optimal combination to assess Alzheimer's‐related pathology in vivo .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Specific associations between plasma levels and both amyloid plaque and tau tangle loads Bars represent the partial Spearman's ρ of amyloid plaque load (blue) and tau tangle load (orange) on plasma levels after adjusting for the other pathology load. In separate models, each biomarker was used as a dependent variable and either amyloid load or tau load as independent variables adjusting for the other pathology measure. We also adjusted for age, sex, and time between blood sampling and death. Numbers inside the bars represent partial Spearman's ρ and numbers above the bars represent the percentual partial Spearman's ρ over the sum of the partial Spearman's ρ of the two pathologies' (%partial ρ = 100*partial ρ/[partial ρplaque + partial ρtangle]). Aβ, amyloid‐β; GFAP, glial fibrillary acidic protein; NfL, neurofilament light; p‐tau, phosphorylated tau.](https://figures.cochat.ai/paper-figures/1c843305447642a2bcacdb4b540ba89a/specific-associations-between-plasma-biomarkers-and-postmortem-amyloid-plaque-figure-2.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, it is important to emphasize that head-to-head studies indicate that different assays for p-tau181 vary substantially in their diagnostic performance9,10 and may not all perform inferiorly to GFAP in all contexts34,43.”
From Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability (2024) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among different p-tau variants, tau phosphorylated at threonine 217 (p-tau217) has demonstrated the highest accuracy in detecting AD pathology and predicting future cognitive decline23,27,29–31.”
From Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests (2024) · cites this paper as [27]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Yet certain p-tau species, but not all, are also associated with neurofibrillary tangle pathology, the secondary AD pathological hallmark.15,16,17”
From Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology (2024) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“Plasma levels of p-tau are strongly associated with PET and CSF biomarkers of AD pathology19–25, neuropathological changes associated with AD20,23,26,27 and the subsequent development of AD dementia20,23,28.”
From Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests (2024) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 3×
“…except NfL ( q = 0.19, P = 0.257) were also associated with the total amount of tangles in the independent models (0.26 ≤ | q | ≤ 0.66, P ≤ 0.016; Fig 1B and (Mirra et al , 1991 ) scale and Braak staging (Braak & Braak, 1991 ) refer to measures of plaque and neurofibrillary tangle, respectively.”
MethodResultInfluentialpROC: an open-source package for R and S+ to analyze and compare ROC curves
Robin, X., Turck, N., Hainard, A., Tiberti, N., Lisacek, F., Sanchez, J.-C., & Müller, M. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-77 · Cited by 13,697
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490
Montine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0910-3 · Cited by 2,894
Self-citationA/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Feldman, H. H., Frisoni, G. B., Hampel, H., Jagust, W. J., Johnson, K. A., Knopman, D. S., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002923 · Cited by 1,864 · cited 1×
“…useful to track AD pathology across the continuum due to its relationship with both main pathological hallmarks of AD, as well as better statistical characteristics of ratios, which can account for production/clearance participants’ inter-variability (Janelidze et al , 2016; Hansson et al , 2019).”
BackgroundSelf-citationHansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700 · cited 1×
“The CSF p-tau/A b 42 ratio has received a lot of attention in recent years, both as a research and a clinical tool (Hansson et al , 2006; Fagan et al , 2007; Li et al , 2007; Snider et al , 2009; Mil (cid:4) a-Alom (cid:4) a et al , 2020; Salvad (cid:1) o & Larsson, 2022).”
MethodSelf-citationPalmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.12134 · Cited by 1,603 · cited 4×
“…markers have the benefit of being significantly cheaper and less invasive than established markers (i.e., cerebrospinal fluid [CSF] and positron emission tomography [PET]), while showing the excellent diagnostic performance (Karikari et al , 2020; Palmqvist et al , 2020; Jane-lidze et al , 2021a).”
BackgroundMethodInfluentialSelf-citationKarikari, T. K., Pascoal, T. A., Ashton, N. J., Janelidze, S., Benedet, A. L., Rodriguez, J. L., Chamoun, M., Savard, M., Kang, M. S., Therriault, J., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30071-5 · Cited by 1,316 · cited 3×
“Although p-tau181 has shown very good performance as an AD biomarker (Karikari et al , 2020, 2021; Thijssen et al , 2020; Jane-lidze et al , 2020a; Grothe et al , 2021), multiple (plasma and CSF) studies support that p-tau217 may be a more useful biomarker than p-tau181, as it has stronger…”
BackgroundResultSelf-citationJanelidze, S., Mattsson, N., Palmqvist, S., Smith, R., Beach, T. G., Serrano, G. E., Chai, X., Proctor, N. K., Eichenlaub, U., Zetterberg, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0755-1 · Cited by 1,247 · cited 4×
“…biomarkers for distinguishing AD from non-AD neurodegenerative disorders (Karikari et al , 2020; Palmqvist et al , 2020; Thijssen et al , 2020; Janelidze et al , 2020a), with noninferior performance compared with CSF and PET markers (Palmqvist et al , 2019; Janelidze et al , 2020a, 2021a;…”
BackgroundMethodInfluentialSelf-citation
Cited by
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., Wessels, A. M., Shcherbinin, S., Wang, H., Monkul Nery, E. S., et al. (2023) · JAMA · doi:10.1001/jama.2023.13239 · Cited by 2,932
Self-citationRevised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Jack, C. R., Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., Graf, A., Hansson, O., Ho, C., Jagust, W., McDade, E., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13859 · Cited by 2,803
Self-citationDiagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology
Ashton, N. J., Brum, W. S., Di Molfetta, G., Benedet, A. L., Arslan, B., Jonaitis, E., Langhough, R. E., Cody, K., Wilson, R., Carlsson, C. M., et al. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2023.5319 · Cited by 884
Self-citationBlood biomarkers for Alzheimer’s disease in clinical practice and trials
Hansson, O., Blennow, K., Zetterberg, H., & Dage, J. (2023) · Nature Aging · doi:10.1038/s43587-023-00403-3 · Cited by 522
Self-citationBarthélemy, N. R., Salvadó, G., Schindler, S. E., He, Y., Janelidze, S., Collij, L. E., Saef, B., Henson, R. L., Chen, C. D., Gordon, B. A., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02869-z · Cited by 448
“Plasma levels of p-tau are strongly associated with PET and CSF biomarkers of AD pathology 19–25 , neuropathological changes associated with AD 20,23,26,27 and the subsequent development of AD dementia 20,23,28 .”
BackgroundSelf-citation
Metadata
- Authors
- Salvadó, G., Ossenkoppele, R., Ashton, N. J., Beach, T. G., Serrano, G. E., Reiman, E. M., Zetterberg, H., Mattsson‐Carlgren, N., Janelidze, S., Blennow, K., & Hansson, O.
- Affiliations
- Lund University (SE)
- King's College London (GB)
- Banner Sun Health Research Institute (US)
- University of Arizona (US)
- Sahlgrenska University Hospital (SE)
- Corresponding author
- Salvadó, Gemma
- Hansson, Oskar
- ORCID
- Venue
- EMBO Molecular Medicine
- Published
- 2023-03-13
- Volume
- 15
- Issue
- 5
- Pages
- e17123-e17123
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC10165361
- OpenAlex
- W4324019853
- Cited by
- 205
- References
- 71
- Citations by year
- 2026: 52 · 2025: 70 · 2024: 62 · 2023: 20
- FWCI
- 35.94
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- EMBO Molecular Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Lund University Publications (Lund University) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, cc-by)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, cc-by)
- Funders
- AD Strategic Fund and Alzheimer's Association (ADSF‐21‐831376‐C, ADSF‐21‐831381‐C, ADSF‐21‐831377‐C)
- ALF‐agreement (ALFGBG‐715986, ALFGBG‐965240)
- Alzheimer Drug Discovery Foundation (201809‐2016862, RDAPB‐201809‐2016615)
- Alzheimer's Association 2021 Zenith Award (ZEN‐21‐848495)
- Bluefield Project
- Erling Persson Family Foundation
- European Research Council (681712, 101053962)
- European Union Joint Program for Neurodegenerative Disorders (JPND2019‐466‐236)
- European Union Joint Programme—Neurodegenerative Disease Research (JPND2021‐00694)
- Greta och Johan Kocks stiftelser
- Hj#x00E4;rnfonden, Sweden (FO2017‐0243, ALZ2022‐0006)
- Knut och Alice Wallenbergs Stiftelse (2017‐0383)
- Konnung Gustaf och Drottning Victorias Frimurarestiftelse
- Marianne and Marcus Wallenberg Foundation (2015.0125)
- Marie Sklodowska‐Curie (101061836, 860197)
- National Institute of Health, USA (1R01AG068398‐01)
- Olav Thon Foundation
- Parkinson Foundation of Sweden (1280/20)
- Skane University Hospital Foundation (2020‐O000028)
- Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (FO2022‐0270)
- Strategic Research Area MultiPark
- Swedish Alzheimer Foundation (AF‐939932, AF‐930351, AF‐939721, AF‐968270)
- Swedish Brain Foundation (FO2021‐0293)
- Swedish Federal Government (2018‐Projekt0279)
- Swedish Research Council (2016‐00906, 2018‐02532, 2017‐00915)
- Swedish State Support for Clinical Research (ALFGBG‐71320)
- UK Dementia Research Institute at UCL (UKDRI‐1003)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, plasma biomarkers, postmortem neuropathology, amyloid plaques, tau tangles, phosphorylated tau, p-tau217, p-tau181, p-tau231, amyloid-beta 42/40 ratio, glial fibrillary acidic protein, neurofilament light chain, biomarker prediction
- MeSH terms
- Neuropathology, Alzheimer Disease, Autopsy, Humans, Biomarkers, Amyloid beta-Peptides, tau Proteins, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads. https://app.cochat.ai/papers/10.15252/emmm.202217123
- The paper
- Salvadó, G., Ossenkoppele, R., Ashton, N. J., Beach, T. G., Serrano, G. E., Reiman, E. M., Zetterberg, H., Mattsson‐Carlgren, N., Janelidze, S., Blennow, K., & Hansson, O. (2023). Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.202217123
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.